{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:32:05Z","timestamp":1768735925630,"version":"3.49.0"},"publisher-location":"Cham","reference-count":58,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031423970","type":"print"},{"value":"9783031423987","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-42398-7_1","type":"book-chapter","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:02:24Z","timestamp":1714723344000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Biomarkers Affecting Moyamoya Disease"],"prefix":"10.1007","author":[{"given":"Yong-Kwang","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Ching","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"3","key":"1_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archneur.1969.00480090076012","volume":"20","author":"J Suzuki","year":"1969","unstructured":"Suzuki J, Takaku A. Cerebrovascular \"moyamoya\" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288\u201399.","journal-title":"Arch Neurol"},{"issue":"12","key":"1_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMra0804622","volume":"360","author":"RM Scott","year":"2009","unstructured":"Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"1_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10143-018-0994-5","volume":"43","author":"S Shang","year":"2020","unstructured":"Shang S, et al. Progress in moyamoya disease. Neurosurg Rev. 2020;43(2):371\u201382.","journal-title":"Neurosurg Rev"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/TACG.S252736","volume":"14","author":"KB Dorschel","year":"2021","unstructured":"Dorschel KB, Wanebo JE. Genetic and proteomic contributions to the pathophysiology of moyamoya angiopathy and related vascular diseases. Appl Clin Genet. 2021;14:145\u201371.","journal-title":"Appl Clin Genet"},{"issue":"12","key":"1_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2176\/nmc.32.883","volume":"32","author":"Y Goto","year":"1992","unstructured":"Goto Y, Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo). 1992;32(12):883\u20136.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"11","key":"1_CR6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S1474-4422(08)70240-0","volume":"7","author":"S Kuroda","year":"2008","unstructured":"Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7(11):1056\u201366.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/jhg.2010.132","volume":"56","author":"F Kamada","year":"2011","unstructured":"Kamada F, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56(1):34\u201340.","journal-title":"J Hum Genet"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1749-6632.1993.tb32280.x","volume":"684","author":"PS Freemont","year":"1993","unstructured":"Freemont PS, The RING, finger. A novel protein sequence motif related to the zinc finger. Ann N Y Acad Sci. 1993;684:174\u201392.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbrc.2007.09.127","volume":"364","author":"M Elangovan","year":"2007","unstructured":"Elangovan M, et al. The ubiquitin-interacting motif of 26S proteasome subunit S5a induces A549 lung cancer cell death. Biochem Biophys Res Commun. 2007;364(2):226\u201330.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1_CR10","doi-asserted-by":"publisher","first-page":"e22542","DOI":"10.1371\/journal.pone.0022542","volume":"6","author":"W Liu","year":"2011","unstructured":"Liu W, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6(7):e22542.","journal-title":"PLoS One"},{"issue":"5","key":"1_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2176\/nmc.52.267","volume":"52","author":"K Houkin","year":"2012","unstructured":"Houkin K, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir (Tokyo). 2012;52(5):267\u201377.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"1","key":"1_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5853\/jos.2015.01760","volume":"18","author":"OY Bang","year":"2016","unstructured":"Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016;18(1):12\u201320.","journal-title":"J Stroke"},{"issue":"2","key":"1_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5853\/jos.2014.16.2.65","volume":"16","author":"M Fujimura","year":"2014","unstructured":"Fujimura M, et al. Genetics and biomarkers of moyamoya disease: significance of RNF213 as a susceptibility gene. J Stroke. 2014;16(2):65\u201372.","journal-title":"J Stroke"},{"issue":"6","key":"1_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jnnp.2009.191817","volume":"81","author":"HS Kang","year":"2010","unstructured":"Kang HS, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81(6):673\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10143-007-0102-8","volume":"31","author":"S Sakamoto","year":"2008","unstructured":"Sakamoto S, et al. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev. 2008;31(1):77\u201381. discussion 81.","journal-title":"Neurosurg Rev"},{"issue":"10","key":"1_CR16","doi-asserted-by":"publisher","first-page":"e47158","DOI":"10.1371\/journal.pone.0047158","volume":"7","author":"YS Park","year":"2012","unstructured":"Park YS, et al. The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization. PLoS One. 2012;7(10):e47158.","journal-title":"PLoS One"},{"issue":"5","key":"1_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, et al. VEGF receptor signalling\u2014in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3892\/etm.2014.1713","volume":"8","author":"J He","year":"2014","unstructured":"He J, et al. Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease. Exp Ther Med. 2014;8(1):302\u20138.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2013.09.019","volume":"63","author":"AS Jaipersad","year":"2014","unstructured":"Jaipersad AS, et al. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63(1):1\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0304-3940(93)90416-I","volume":"160","author":"A Takahashi","year":"1993","unstructured":"Takahashi A, et al. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett. 1993;160(2):214\u20136.","journal-title":"Neurosci Lett"},{"issue":"12","key":"1_CR21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/01.STR.27.12.2160","volume":"27","author":"T Yoshimoto","year":"1996","unstructured":"Yoshimoto T, et al. Angiogenic factors in moyamoya disease. Stroke. 1996;27(12):2160\u20135.","journal-title":"Stroke"},{"issue":"6","key":"1_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1161\/01.STR.29.6.1188","volume":"29","author":"M Yamamoto","year":"1998","unstructured":"Yamamoto M, et al. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke. 1998;29(6):1188\u201393.","journal-title":"Stroke"},{"issue":"12","key":"1_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/01.CIR.0000012146.07240.FD","volume":"105","author":"R Morishita","year":"2002","unstructured":"Morishita R, et al. Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 2002;105(12):1491\u20136.","journal-title":"Circulation"},{"issue":"12","key":"1_CR24","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1161\/01.STR.0000148237.13659.e6","volume":"35","author":"R Nanba","year":"2004","unstructured":"Nanba R, et al. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke. 2004;35(12):2837\u201342.","journal-title":"Stroke"},{"issue":"2","key":"1_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1227\/01.NEU.0000249275.87310.FF","volume":"60","author":"Y Takagi","year":"2007","unstructured":"Takagi Y, et al. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease. Neurosurgery. 2007;60(2):338\u201345. discussion 345","journal-title":"Neurosurgery"},{"issue":"4","key":"1_CR26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1177\/0271678X16658301","volume":"37","author":"KG Blecharz","year":"2017","unstructured":"Blecharz KG, et al. Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease. J Cereb Blood Flow Metab. 2017;37(4):1527\u201339.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"8209313","DOI":"10.1155\/2020\/8209313","volume":"2020","author":"J Yu","year":"2020","unstructured":"Yu J, et al. Significance of serum angiopoietin-2 in patients with hemorrhage in adult-onset Moyamoya disease. Biomed Res Int. 2020;2020:8209313.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/STROKEAHA.108.529420","volume":"40","author":"N Rafat","year":"2009","unstructured":"Rafat N, et al. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke. 2009;40(2):432\u20138.","journal-title":"Stroke"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fmed.2018.00295","volume":"5","author":"KE Paschalaki","year":"2018","unstructured":"Paschalaki KE, Randi AM. Recent advances in endothelial colony forming cells toward their use in clinical translation. Front Med (Lausanne). 2018;5:295.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1_CR30","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/jcbfm.2008.1","volume":"28","author":"T Yoshihara","year":"2008","unstructured":"Yoshihara T, et al. Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab. 2008;28(6):1086\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"1_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jnr.22228","volume":"88","author":"JH Kim","year":"2010","unstructured":"Kim JH, et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res. 2010;88(3):510\u20138.","journal-title":"J Neurosci Res"},{"issue":"7","key":"1_CR32","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/ATVBAHA.115.305363","volume":"35","author":"JY Lee","year":"2015","unstructured":"Lee JY, et al. Deregulation of retinaldehyde dehydrogenase 2 leads to defective angiogenic function of endothelial colony-forming cells in Pediatric moyamoya disease. Arterioscler Thromb Vasc Biol. 2015;35(7):1670\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1_CR33","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3171\/2017.5.JNS17147","volume":"129","author":"JW Choi","year":"2018","unstructured":"Choi JW, et al. Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J Neurosurg. 2018;129(5):1151\u20139.","journal-title":"J Neurosurg"},{"issue":"2","key":"1_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3171\/2013.9.JNS131000","volume":"120","author":"HS Kang","year":"2014","unstructured":"Kang HS, et al. Smooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell model. J Neurosurg. 2014;120(2):415\u201325.","journal-title":"J Neurosurg"},{"issue":"5","key":"1_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ajhg.2009.04.007","volume":"84","author":"DC Guo","year":"2009","unstructured":"Guo DC, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009;84(5):617\u201327.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"1_CR36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/jcbfm.2008.67","volume":"28","author":"KH Jung","year":"2008","unstructured":"Jung KH, et al. Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab. 2008;28(11):1795\u2013803.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1_CR37","first-page":"37","volume":"60","author":"K Tokunaga","year":"2008","unstructured":"Tokunaga K, Date I. Moyamoya disease. Brain Nerve. 2008;60(1):37\u201342.","journal-title":"Brain Nerve"},{"issue":"4","key":"1_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3171\/jns.1998.89.4.0623","volume":"89","author":"M Hojo","year":"1998","unstructured":"Hojo M, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998;89(4):623\u20139.","journal-title":"J Neurosurg"},{"issue":"9","key":"1_CR39","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1161\/01.STR.28.9.1733","volume":"28","author":"M Yamamoto","year":"1997","unstructured":"Yamamoto M, et al. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke. 1997;28(9):1733\u20138.","journal-title":"Stroke"},{"issue":"1","key":"1_CR40","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1038\/s41598-017-03278-8","volume":"7","author":"L Weng","year":"2017","unstructured":"Weng L, et al. Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep. 2017;7(1):3071.","journal-title":"Sci Rep"},{"issue":"30","key":"1_CR41","doi-asserted-by":"publisher","first-page":"21486","DOI":"10.1016\/S0021-9258(19)36635-9","volume":"267","author":"JF Boylan","year":"1992","unstructured":"Boylan JF, Gudas LJ. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem. 1992;267(30):21486\u201391.","journal-title":"J Biol Chem"},{"issue":"12","key":"1_CR42","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1161\/01.STR.0000100159.43123.D7","volume":"34","author":"SK Kim","year":"2003","unstructured":"Kim SK, et al. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke. 2003;34(12):2835\u201341.","journal-title":"Stroke"},{"issue":"11","key":"1_CR43","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1177\/0271678X18768443","volume":"38","author":"KG Blecharz-Lang","year":"2018","unstructured":"Blecharz-Lang KG, et al. Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease. J Cereb Blood Flow Metab. 2018;38(11):1940\u201353.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"1_CR44","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.surneu.2008.10.009","volume":"72","author":"M Fujimura","year":"2009","unstructured":"Fujimura M, et al. Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol. 2009;72(5):476\u201380. discussion 480","journal-title":"Surg Neurol"},{"issue":"11","key":"1_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1468-1331.2011.03393.x","volume":"18","author":"G Ni","year":"2011","unstructured":"Ni G, et al. Increased levels of circulating SDF-1alpha and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol. 2011;18(11):1304\u20139.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1_CR46","doi-asserted-by":"publisher","first-page":"e0169714","DOI":"10.1371\/journal.pone.0169714","volume":"12","author":"JH Phi","year":"2017","unstructured":"Phi JH, et al. Chemokine ligand 5 (CCL5) derived from endothelial colony-forming cells (ECFCs) mediates recruitment of smooth muscle progenitor cells (SPCs) toward critical vascular locations in Moyamoya disease. PLoS One. 2017;12(1):e0169714.","journal-title":"PLoS One"},{"issue":"10","key":"1_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2176\/nmc.ra.2019-0059","volume":"59","author":"T Mikami","year":"2019","unstructured":"Mikami T, et al. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease. Neurol Med Chir (Tokyo). 2019;59(10):361\u201370.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.brainres.2017.11.013","volume":"1679","author":"M Fujimura","year":"2018","unstructured":"Fujimura M, et al. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: involvement of intrinsic immune reaction in its pathogenesis. Brain Res. 2018;1679:39\u201344.","journal-title":"Brain Res"},{"issue":"4","key":"1_CR49","doi-asserted-by":"publisher","first-page":"e36386","DOI":"10.1371\/journal.pone.0036386","volume":"7","author":"R Lin","year":"2012","unstructured":"Lin R, et al. Clinical and immunopathological features of Moyamoya disease. PLoS One. 2012;7(4):e36386.","journal-title":"PLoS One"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1750-1172-8-45","volume":"8","author":"TK Sigdel","year":"2013","unstructured":"Sigdel TK, et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients. Orphanet J Rare Dis. 2013;8:45.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/1747493016662039","volume":"11","author":"OY Bang","year":"2016","unstructured":"Bang OY, et al. Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. Int J Stroke. 2016;11(9):999\u20131008.","journal-title":"Int J Stroke"},{"issue":"11","key":"1_CR52","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1161\/STROKEAHA.118.021888","volume":"49","author":"JW Chung","year":"2018","unstructured":"Chung JW, et al. Cav-1 (Caveolin-1) and arterial remodeling in adult Moyamoya disease. Stroke. 2018;49(11):2597\u2013604.","journal-title":"Stroke"},{"issue":"2","key":"1_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1161\/01.RES.0000136344.27825.72","volume":"95","author":"P Sonveaux","year":"2004","unstructured":"Sonveaux P, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res. 2004;95(2):154\u201361.","journal-title":"Circ Res"},{"issue":"11","key":"1_CR54","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s007010070025","volume":"142","author":"A Noda","year":"2000","unstructured":"Noda A, et al. Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease. Acta Neurochir. 2000;142(11):1275\u20139. discussion 1279-80","journal-title":"Acta Neurochir"},{"issue":"11","key":"1_CR55","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00381-011-1504-z","volume":"27","author":"YS Park","year":"2011","unstructured":"Park YS, et al. Age-specific eNOS polymorphisms in moyamoya disease. Childs Nerv Syst. 2011;27(11):1919\u201326.","journal-title":"Childs Nerv Syst"},{"issue":"12","key":"1_CR56","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.028","volume":"26","author":"D Kashiwazaki","year":"2017","unstructured":"Kashiwazaki D, Uchino H, Kuroda S. Downregulation of apolipoprotein-E and apolipoprotein-J in moyamoya disease-a proteome analysis of cerebrospinal fluid. J Stroke Cerebrovasc Dis. 2017;26(12):2981\u20137.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"1_CR57","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00701-010-0711-9","volume":"152","author":"C Roder","year":"2010","unstructured":"Roder C, et al. Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir. 2010;152(12):2153\u201360.","journal-title":"Acta Neurochir"},{"issue":"4","key":"1_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/092986732304160204181543","volume":"23","author":"G Bedini","year":"2016","unstructured":"Bedini G, et al. Vasculogenic and angiogenic pathways in moyamoya disease. Curr Med Chem. 2016;23(4):315\u201345.","journal-title":"Curr Med Chem"}],"container-title":["Advances and Technical Standards in Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-42398-7_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:02:35Z","timestamp":1714723355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-42398-7_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031423970","9783031423987"],"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-42398-7_1","relation":{},"ISSN":["0095-4829","1869-9189"],"issn-type":[{"value":"0095-4829","type":"print"},{"value":"1869-9189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"4 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}